by Pollen Williamson | Sep 26, 2017 | Content
According to NIDA Director Dr. Nora Volkow, “NIH and NIDA are committed to an ‘all scientific hands on deck’ effort to end the opioid crisis in America by halving the time it takes to develop new medications to treat pain and addiction and reverse overdoses.” The...
by Pollen Williamson | Sep 20, 2017 | Content
The U.S. Food and Drug Administration (FDA) is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS). The combined use of...
by Pollen Williamson | Sep 7, 2017 | Content
Today, SAMHSA released the latest findings from the 2016 National Survey on Drug Use and Health (NSDUH), which provides the estimates on substance use and mental health in the United States, including the misuse of opioids. In 2016, there were 11.8 million people ages...
by Pollen Williamson | Sep 1, 2017 | Content
The North Carolina State Opioid Treatment Authority is encouraging all opioid treatment programs to review current policies and their ability to respond if a program is flooded or otherwise deemed unsafe due to storm damage, and ensure records are accessible to...
by Pollen Williamson | Aug 29, 2017 | Content
The California Health Care Foundation distributed a report based on a review of the current literature related to buprenorphine, with a focus on identifying best practices in place or emerging around the integration of MAT into primary care setting, as well as...
Recent Comments